Abstract Objective To investigate the relationship between triglyceride-glucose index (TyG) and the risk of non-alcoholic fatty liver disease (NAFLD) in patients with polycystic ovary syndrome (PCOS). Methods A total of 350 PCOS patients admitted to the Department of Endocrinology and Metabolism, Renji Hospital, Shanghai Jiao Tong University School of Medicine from January 2017 to December 2020 were selected. According to whether they had NAFLD or not, they were divided into NAFLD group (201 cases) and non-NAFLD group (149 cases). TyG, lipid accumulation index (LAP) and visceral adiposity index (VAI) were calculated. Spearman correlation coefficient was used to analyze the correlation between TyG and liver function, glucolipid metabolism and reproductive indexes. Logistic univariate and multivariate analysis was used to analyze the correlation between TyG, LAP, VAI, and NAFLD in PCOS patients. Results There were statistically significant differences in clinical indicators, TyG, LAP, and VAI between the two groups (P ＜ 0.05). Correlation analysis showed that TyG was positively correlated with glutamic-pyruvic transaminase, glutamic-oxalacetic transaminase, γ-glutamyl transpeptidase, total cholesterol, low density lipoprotein cholesterol, area under insulin curve and free androgen index (rs ＞ 0, P ＜ 0.05). And it was negatively correlated with high density lipoprotein cholesterol, sex hormone-binding globulin, and anti-Müllerian hormone (rs ＜ 0, P ＜ 0.05). Univariate logistic regression analysis showed that age, body mass index, homeostasis model assessment-IR, free androgen index, glutamic-pyruvic transaminase, TyG, LAP, and VAI were all risk factors for NAFLD in PCOS patients (OR ＞ 1, P ＜ 0.05). In order to compare the relationship between TyG, LAP, VAI, and NAFLD in PCOS patients and avoid the interaction between the indexes, they were stratified by quartile, and the subjects were included in four subgroups of every index, respectively. Multivariate logistic regression was performed to correct confounding factors. The results showed that TyG ＞ 7.95, LAP ＞ 15.85, and VAI ＞ 1.91 were independent risk factors for NAFLD in PCOS patients (OR ＞ 1, P ＜ 0.05). Conclusion TyG index has certain value for the auxiliary diagnosis of NAFLD in PCOS patients.
FU Jiarong ZHU Yuchen YU Jie LIU Wei TAO Tao. Association of triglyceride-glucose index with risk of non-alcoholic fatty liver disease in patients with polycystic ovary syndrome[J]. 中国医药导报, 2021, 18(28): 98-102.
[1] Escobar-Morreale HF. Polycystic ovary syndrome：definition，aetiology，diagnosis and treatment [J]. Nat Rev Endocrinol，2018，14（5）：270-284.
[2] Wekker V，van Dammen L，Koning A，et al. Long-term cardiometabolic disease risk in women with PCOS：a systematic review and meta-analysis [J]. Hum Reprod Update，2020，26（6）：942-960.
[3] Hoeger KM，Dokras A，Piltonen T. Update on PCOS：Consequences，Challenges，and Guiding Treatment [J]. J Clin Endocrinol Metab，2021，106（3）：e1071-e1083.
[4] Lonardo A，Mantovani A，Lugari S，et al. NAFLD in Some Common Endocrine Diseases：Prevalence，Pathophysiology，and Principles of Diagnosis and Management [J]. Int J Mol Sci，2019，20（11）：2841.
[5] Chalasani N，Younossi Z，Lavine JE，et al. The diagnosis and management of nonalcoholic fatty liver disease：Practice guidance from the American Association for the Study of Liver Diseases [J]. Hepatology，2018，67（1）：328-357.
[6] Castera L，Friedrich-Rust M，Loomba R. Noninvasive Assessment of Liver Disease in Patients With Nonalcoholic Fatty Liver Disease [J]. Gastroenterology，2019，156（5）：1264-1281.e4.
[7] 中华医学会肝病学分会脂肪肝和酒精性肝病学组，中国医师协会脂肪性肝病专家委员会.非酒精性脂肪性肝病防治指南（2018更新版）[J].中华肝脏病杂志，2018，26（3）：195-203.
[8] Brahimaj A，Rivadeneira F，Muka T，et al. Novel metabolic indices and incident type 2 diabetes among women and men：the Rotterdam Study [J]. Diabetologia，2019，62（9）：1581-1590.
[9] Mazidi M，Kengne AP，Katsiki N，et al. Lipid accumulation product and triglycerides/glucose index are useful predictors of insulin resistance [J]. J Diabetes Complications，2018，32（3）：266-270.
[10] Park K，Ahn CW，Lee SB，et al. Elevated TyG Index Predicts Progression of Coronary Artery Calcification [J]. Diabetes Care，2019，42（8）：1569-1573.
[11] Shiha G，Korenjak M，Eskridge W，et al. Redefining fatty liver disease：an international patient perspective [J]. Lancet Gastroenterol Hepatol，2021，6（1）：73-79.
[12] Rotterdam ESHRE/ASRM-Sponsored PCOS consensus workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome（PCOS）[J]. Hum Reprod，2004，19（1）：41-47.
[13] Chalasani N，Younossi Z，Lavine JE，et al. The diagnosis and management of non-alcoholic fatty liver disease：practice guideline by the American Gastroenterological Association，American Association for the Study of Liver Diseases，and American College of Gastroenterology [J].Gastroenterology，2012，142（7）：1592-1609.
[14] Matthews DR，Hosker JP，Rudenski AS，et al. Homeostasis model assessment：insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man [J]. Diabetologia，1985，28（7）：412-419.
[15] Matsuda M，DeFronzo RA. Insulin sensitivity indices obtained from oral glucose tolerance testing：comparison with the euglycemic insulin clamp [J]. Diabetes Care，1999， 22（9）：1462-1470.
[16] Guerrero-Romero F，Simental-Mendía LE，González-Ortiz M，et al. The product of triglycerides and glucose，a simple measure of insulin sensitivity. Comparison with the euglycemic-hyperinsulinemic clamp [J]. J Clin Endocrinol Metab，2010，95（7）：3347-3351.
[17] Kahn HS. The“lipid accumulation product”performs better than the body mass index for recognizing cardiovascular risk：a population-based comparison [J]. BMC Cardiovasc Disord，2005，5（1）：26.
[18] Amato MC，Giordano C，Galia M，et al. Visceral Adiposity Index：a reliable indicator of visceral fat function associated with cardiometabolic risk [J]. Diabetes Care，2010， 33（4）：920-922.
[19] Kitae A，Hashimoto Y，Hamaguchi M，et al. The Triglyceride and Glucose Index Is a Predictor of Incident Nonalcoholic Fatty Liver Disease：A Population-Based Cohort Study [J]. Can J Gastroenterol Hepatol，2019，2019：5121574.
[20] Lee SB，Kim MK，Kang S，et al. Triglyceride Glucose Index Is Superior to the Homeostasis Model Assessment of Insulin Resistance for Predicting Nonalcoholic Fatty Liver Disease in Korean Adults [J]. Endocrinol Metab（Seoul），2019，34（2）：179-186.
[21] Khan RS，Bril F，Cusi K，et al. Modulation of Insulin Resistance in Nonalcoholic Fatty Liver Disease [J]. Hepatology，2019，70（2）：711-724.
[22] Smith GI，Shankaran M，Yoshino M，et al. Insulin resistance drives hepatic de novo lipogenesis in nonalcoholic fatty liver disease [J]. J Clin Invest，2020，130（3）：1453-1460.
[23] 吴挺丰，廖献花，钟碧慧.中国部分地区非酒精性脂肪肝病的流行情况[J].临床肝胆病杂志，2020，36（6）：1370-1373.
[24] Kato K，Takeshita Y，Misu H，et al. Liver steatosis is associated with insulin resistance in skeletal muscle rather than in the liver in Japanese patients with non-alcoholic fatty liver disease [J]. J Diabetes Investig，2015，6（2）：158-163.
[25] Zhou X，庞梦圆，华瑞.中国中产阶级人群非酒精性脂肪肝的独立标志物[J].临床肝胆病杂志，2019，35（5）：1128.
[26] Watt MJ，Miotto PM，De Nardo W，et al. The Liver as an Endocrine Organ-Linking NAFLD and Insulin Resistance [J]. Endocr Rev，2019，40（5）：1367-1393.
